Catalyst Pharmaceuticals, Inc

Catalyst is anchored in the United States, which management describes as the cornerstone of its commercial strategy and where nearly all reported product revenue is generated. The company also has selective international exposure through partners, including Canada for FIRDAPSE® and Japan for FIRDAPSE®, with AGAMREE® being evaluated for Canadian commercialization. This makes the business primarily U.S.-driven, but with some partner-led geographic diversification that can extend product life cycles and broaden the addressable market. Geography matters because the company depends on local regulatory approvals, reimbursement systems, and supply arrangements in each market. It also faces cross-border sourcing and tariff exposure because active ingredients and finished products are obtained from both U.S. and foreign suppliers.

Catalyst's biggest business risk is dependence on successful commercialization of a small number of orphan products, where patient populations are limited and market share must be high to support economics. Access and reimbursement are critical because physicians and patients may want the therapy, but payor coverage, prior authorization, and pricing policies determine actual uptake. The company also faces patent, exclusivity, and generic-entry risk, especially for FIRDAPSE®, where litigation and the timing of exclusivity expiration can materially affect future revenue. Supply-chain and tariff exposure is meaningful because the company sources APIs and finished products from both U.S. and foreign suppliers and has long-term third-party supply commitments. More broadly, rare-disease pharma companies face regulatory, reimbursement, and competitive risks, plus the possibility that acquisitions or in-licensing efforts do not produce value.